🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Suraksha Diagnostic Limited SURAKSHA NSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.surakshanet.com
Company Profile ↓
₹289.95
-3.30% 1Y
Mkt Cap₹1,510.08 Cr
P/E42.14
P/B6.70
Div. Yield0.16%
52W High₹356.00
52W Low₹227.60
Book Value₹47.17
EPS (TTM)₹6.88

Company Overview

Suraksha Diagnostic Limited provides pathological and radiological services through diagnostic centers in India. It offers home collection services; pathology services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, haematology, clinical biochemistry and immunology, immunohistochemistry, fluorescence in-situ hybridization, cytogenetics, flow cytometry, newborn screening, and NGS. The company also provides microarray, QF-PCR, FISH, karyotyping, and NIPT services; X-Ray, MRI scan, CT scan, USG, DEXA scan, Mammography, OPG radiology services; ECG, echocardiogram, stress test and treadmill test, wireless holter monitoring, and PFT cardiology services; EEG, EMG, and NCV neurology services; and upper GI and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy gastroenterology services. In addition, it offers clinic services, including dental, physiotherapy, immunology and rheumatology, ENT, eye, and specialty clinics, as well as fetal care; home doctor visit services; online doctor consultation; and doctor curated lab packages for bone and health, men's and women's health, senior citizens, diabetes care, fever, full-body checkups, and at-home packages. The company was founded in 1992 and is based in Kolkata, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 70.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.7% CAGR over the past five years.

Healthy Margins

Operating margin of 21.8% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹310.41 Cr (+23.1% YoY); net profit ₹32.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +20.7%, earnings +38.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.7%, profit CAGR 70.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:17.75%
1 Year:20.70%

Compounded Profit Growth

5 Years:70.31%
1 Year:38.90%

Stock Price Performance

1 Year:-3.30%
6 Months:+3.47%
3 Months:+11.86%
1 Month:-16.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 49% of range
₹227.60 ₹356.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)31.31 · Neutral
Price Performance
1M-16.94%
3M+11.86%
6M+3.47%
1Y-3.30%
Valuation vs Sector

P/E of 42.14 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 17.7% over 5 years.
  • Profit CAGR of 70.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
42.14
Industry PE
36.43
Forward P/E
29.59
PEG Ratio
-
Book Value
₹47.17
Price to Book
6.70
P/S
5.06
EV/EBITDA
15.96
Dividend Yield
0.16%

Growth (CAGR)

Revenue 5Y
17.75%
Profit 5Y
70.31%
Revenue (YoY)
20.70%
Earnings (YoY)
38.90%

Profitability & Returns

ROCE
14.70%
ROE
13.15%
ROA
7.18%
Profit Margin
11.00%
Op Margin
21.80%
Gross Margin
88.41%
EPS (Latest Qtr)
₹1.21
EPS (TTM)
₹6.88

Balance Sheet & Liquidity

Debt/Equity
0.54
Quick Ratio
0.91
Current Ratio
1.05
Debt
₹130.34 Cr
Total Assets
₹448.12 Cr
Current Assets
₹62.58 Cr
Working Capital
₹2.93 Cr

Ownership

Promoter Holding
61.97%
Chg in Prom Hold
12.87%
FII / Inst Holding
21.47%
Chg in FII Hold
-1.00%

Financial Snapshot

Enterprise Value
₹1,510.08 Cr
Total Revenue (TTM)
₹325.47 Cr
EBITDA
₹107.32 Cr
Free Cash Flow
₹14.48 Cr
Operating Cash Flow
₹81.83 Cr
Shares Outstanding
₹5.21 Cr
Gross Margin
88.41%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SURAKSHA Suraksha Diagnostic Limited NSEPHARMA 289.95 42.14 ₹1,510.08 Cr 0.16% 14.70% 13.15% 17.75% 70.31%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 60.05 Cr51.82 Cr55.19 Cr60.73 Cr66.75 Cr59.51 Cr65.09 Cr72.59 Cr78.73 Cr77.69 Cr81.41 Cr
Cost of Revenue ------8.85 Cr8.75 Cr8.90 Cr8.67 Cr10.16 Cr
Gross Profit ------56.25 Cr63.84 Cr69.83 Cr69.02 Cr71.25 Cr
Operating Expenses 39.22 Cr36.50 Cr35.72 Cr40.12 Cr43.55 Cr41.26 Cr44.99 Cr50.46 Cr55.65 Cr55.57 Cr57.85 Cr
Operating Income 12.88 Cr7.40 Cr11.11 Cr11.62 Cr14.45 Cr9.42 Cr11.26 Cr13.38 Cr14.18 Cr13.45 Cr13.41 Cr
EBITDA 20.83 Cr15.32 Cr19.47 Cr20.61 Cr23.20 Cr18.25 Cr20.00 Cr24.66 Cr24.97 Cr23.78 Cr25.15 Cr
Interest Expense 2.48 Cr2.03 Cr2.08 Cr2.22 Cr2.13 Cr1.98 Cr2.06 Cr2.70 Cr2.78 Cr3.16 Cr3.92 Cr
Pretax Income 10.96 Cr6.22 Cr9.23 Cr10.52 Cr13.63 Cr8.04 Cr9.21 Cr12.47 Cr12.05 Cr10.06 Cr9.98 Cr
Tax Provision 2.63 Cr1.68 Cr2.91 Cr2.84 Cr3.48 Cr2.06 Cr2.04 Cr3.29 Cr3.22 Cr2.82 Cr3.82 Cr
Net Income 8.34 Cr4.53 Cr6.32 Cr7.67 Cr10.15 Cr5.98 Cr7.39 Cr9.40 Cr8.99 Cr7.52 Cr6.28 Cr
Diluted EPS 121.8867.3994.491.842.401.181.421.801.731.441.21

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 158.00 Cr140.00 Cr-190.13 Cr218.71 Cr252.09 Cr310.41 Cr
Cost of Revenue ---27.40 Cr27.25 Cr29.52 Cr36.48 Cr
Gross Profit ---162.73 Cr191.46 Cr222.57 Cr273.94 Cr
Operating Expenses 123.00 Cr115.00 Cr-146.95 Cr150.49 Cr174.44 Cr219.53 Cr
Operating Income 21.00 Cr9.00 Cr-15.78 Cr40.97 Cr48.13 Cr54.41 Cr
EBITDA 34.00 Cr25.00 Cr-47.48 Cr72.84 Cr85.09 Cr98.56 Cr
Interest Expense 2.00 Cr2.00 Cr-9.06 Cr8.79 Cr8.39 Cr12.55 Cr
Pretax Income 21.00 Cr6.00 Cr-6.75 Cr31.45 Cr41.41 Cr44.56 Cr
Tax Provision 5.88 Cr-6.00 L-68.30 L8.33 Cr10.43 Cr13.15 Cr
Net Income 15.00 Cr6.00 Cr-6.52 Cr23.63 Cr31.82 Cr32.19 Cr
Diluted EPS 220.4393.334.001.254.545.97-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 173.00 Cr171.00 Cr-281.19 Cr300.20 Cr333.52 Cr448.12 Cr
Current Assets ---68.05 Cr72.45 Cr47.15 Cr62.58 Cr
Cash & Equivalents ---2.16 Cr2.52 Cr2.25 Cr3.21 Cr
Inventory ---6.16 Cr6.68 Cr8.05 Cr8.14 Cr
Receivables ---4.68 Cr8.87 Cr13.81 Cr22.76 Cr
Total Liabilities ---125.73 Cr121.06 Cr123.29 Cr204.64 Cr
Current Liabilities ---38.34 Cr39.41 Cr42.72 Cr59.65 Cr
Long Term Debt ---8.44 Cr5.18 Cr2.88 Cr17.76 L
Total Debt 13.00 Cr18.00 Cr-96.87 Cr90.48 Cr88.89 Cr130.34 Cr
Total Equity 118.00 Cr125.00 Cr-155.93 Cr179.41 Cr211.24 Cr244.85 Cr
Shares Outstanding ---5.21 Cr5.21 Cr5.21 Cr5.21 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 31.00 Cr24.00 Cr-44.10 Cr60.48 Cr63.36 Cr81.83 Cr
Investing Cash Flow -20.00 Cr-28.00 Cr--20.80 Cr-35.00 Cr-39.58 Cr-52.17 Cr
Financing Cash Flow -10.00 Cr3.00 Cr--24.33 Cr-25.13 Cr-24.05 Cr-28.69 Cr
Capital Expenditure -16.00 Cr-16.00 Cr--13.17 Cr-45.47 Cr-42.02 Cr-67.34 Cr
Free Cash Flow 15.00 Cr8.00 Cr-30.93 Cr15.01 Cr21.34 Cr14.48 Cr
Net Change in Cash 1.00 Cr-1.00 Cr--1.03 Cr35.74 L-27.32 L96.73 L

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---85.6%87.5%88.3%88.2%
Operating Margin % 13.3%6.4%-8.3%18.7%19.1%17.5%
Net Margin % 9.5%4.3%-3.4%10.8%12.6%10.4%
ROE % 12.7%4.8%-4.2%13.2%15.1%13.1%
ROCE % ---6.5%15.7%16.6%14.0%

Shareholding Pattern

Insiders
61.97%
Institutions
21.47%
Public Float
56.45%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SURAKSHA

Google News hu, 13 Aug 2026

Suraksha Diagnostic Ltd (NSE:SURAKSHA) (Q1 2027) Earnings Call Highlights: Strong 21% Revenue ... - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQRmNjUWxvU0UySVhFdUUxazViU3M4Unl3Sno3RnpEUGFSRk9lUFU0WXpId3BGMkxTV25qamNxQnRoYVBNY0sxRXk3N2pTNVNoQmtwN1BpQVdZa2Y4THc4UElnWVlKbEpoN1lqUGdvQWc4MENEOExzMzhJajc5Uks5bmxvM3RRNDBIeFFVbz…

Google News hu, 20 Aug 2026

SURAKSHA Stock Price and Chart — NSE:SURAKSHA - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5Fd2Z1Q25QYm9aQldfdVo1dkltdW9DMElzblZPRWJMU3BPQlZNN3JSbUhES01lVnQ0NFBmTzVNbXRXX2FlUXp3NXJZUHBVQXJvNDN1a01yVFZVYTYwTHc?oc=5" target="_blank">SURAKSHA Stock Price and Chart — NSE:SUR…

Google News Fri, 09 Oct 2026

Here's Why We Think Suraksha Diagnostic (NSE:SURAKSHA) Might Deserve Your Attention Today - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNNXFtVmVKNHZqS2JPNVpkV3M4akRybkFpTTFJSVRvb0dTaWtCdFV4MmhYb0UwUHY1ZlpISVJ5Z0VZcjdIR19Ha1RkSGxwdW9LclVMSTRxMWZQRHcxV3EtSVZwTTlkZzU3S0gzRklSRFVOQXhoeEw0S1VDR3dCWnJZRU1Fem1mTzdud0pzNH…

Google News Wed, 12 Aug 2026

Suraksha Diagnostic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOZ2wtSS1keVV1V0FTVnlYRHVUbzZtZkNvbkhXZDZKaTFsTnp3VG9TZlEtNEhwd3dOYktUajNmWm1iUG9sUkQzblhLSmkzdUNMMkxMSGUtU1NnWGU2dV81eVJpSGp5X1Y1Tmw0R3gzN0pYemQwQTVYb2tmaEV4dTJvUm5ZSS1RWHdfOFdXS0…

Google News Wed, 14 Oct 2026

Suraksha Diagnostic pays ₹2,360 fine for shareholding filing delay - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNUXJqR0diUjdPa3NyUGloX0ZGRjhubzFCV3E5OWZxdnJPd2VmeXJQSlI1OGE0bS1wNE9vbkR0dHlLV3ZncS1lS21na1A3eXhHcjBHOTltU3VlUXppM1VVSFRaWFF6ZUdiRFl2TUo3YTRqWDd6VGlYMDBqQmRYN25Jbkw4RGxEYkl3T1o4SW…

Google News Fri, 25 Sep 2026

Suraksha Diagnostic Share: Bull Case vs Bear Case for 2026 - Univest

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOZ2pBZVIyeGZCYTREX1A2bVZjaUtHNjN3YWY2UkpfMGZRVEdEclpRaGFXV0xtZkZKcFZyZlJhaGNha2tSejdudDVKMm5kZkNBWHhDY3hQUlJBSmYwbmtQV05vWDFUMlNrMFJ3OXBKd2pIZ1E1S280c3k4ZlRSd29ZWXYwUTg?oc=5" targ…

SURAKSHA — Frequently Asked Questions

What is the current share price of Suraksha Diagnostic Limited (SURAKSHA)?

As of 2026-10-23 04:58 IST, Suraksha Diagnostic Limited (SURAKSHA) trades at ₹289.95 on NSE. Its 52-week range is ₹227.60 to ₹356.00.

What is the market capitalisation of SURAKSHA?

Suraksha Diagnostic Limited (SURAKSHA) has a market capitalisation of ₹1,510.08 Cr on NSE.

What is the P/E ratio of SURAKSHA?

SURAKSHA trades at a trailing price-to-earnings (P/E) ratio of 42.14. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 6.70.

Does SURAKSHA pay a dividend?

Suraksha Diagnostic Limited (SURAKSHA) currently offers a dividend yield of 0.16%.

What is the return on equity (ROE) of SURAKSHA?

SURAKSHA has a return on equity (ROE) of 13.15%. Its return on capital employed (ROCE) is 14.70%.

Is SURAKSHA a good stock to buy?

This page provides a data-driven analysis of Suraksha Diagnostic Limited (SURAKSHA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space